KDM1A and acute myeloid leukemia: Based on these recent findings, 3 different KDM1A small molecule inhibitors, namely tranylcypomine, GSK-LSD1, and ORY-1001, are currently in phase I/II clinical studies for AML and small cell lung carcinoma (140).